Clinical Trials Logo

Hyperlipoproteinemia Type I clinical trials

View clinical trials related to Hyperlipoproteinemia Type I.

Filter by:

NCT ID: NCT02098278 Completed - Clinical trials for Hypertriglyceridemia

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride clearance. This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.

NCT ID: NCT01589237 Completed - Clinical trials for Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Start date: February 2013
Phase: Phase 3
Study type: Interventional

This study is to determine long-term safety and tolerability, and continued efficacy in lowering triglycerides of LCQ908 in subjects with Familial Chylomicronemia Syndrome (FCS) (HLP type I).

NCT ID: NCT01514461 Completed - Clinical trials for Familial Chylomicronemia Syndrome (FCS)

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia [HLP] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type 1).

NCT ID: NCT00891306 Completed - Clinical trials for Familial Lipoprotein Lipase Deficiency

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Start date: February 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This trial is designed to expand the currently available data on the safety and efficacy of alipogene tiparvovec treatment in lipoprotein lipase deficiency (LPLD) and to further the understanding of possible mechanisms of action of the therapy.